Views & Analysis
Celltrion gears up for subcutaneous infliximab launch in Eur...
Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p